Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: a preliminary study.
Multiple myeloma (MM) is a malignancy of B lymphocytes or plasma cells. It is a biologically complex disease characterized by excessive numbers of abnormal plasma cells in the bone marrow, and overproduction of intact monoclonal immunoglobulin of a single type . It is the second most common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths . In Malaysia, more than 50% of myeloma patients are diagnosed at the late stage of the disease, and MM is more prevalent in men than women . Gene expression changes, translocations, mutations, chromosomal deletions, and epigenetic changes are key factors underlying the molecular pathogenesis of MM [4-6]. Although recent advances in treatment strategies have improved survival and quality of life in patients with MM, MM is still an incurable disease. Drug resistance remains the main problem in MM patients.
Nicotinamide (NAM) phosphoribosyltransferase (NAMPT) is a key enzyme involved in nicotinamide adenine dinucleotide ([NAD.sup.+]) salvage pathway . Overexpression of NAMPT has been found in various human malignancies including ovarian, breast, colorectal, gastric, prostate, well-differentiated thyroid and endometrial carcinomas, and MM, melanoma, astrocytoma, and lymphoma . The elevated expression of NAMPT gene promotes tumorigenesis through constant NAD resynthesis to provide adequate energy for rapidly proliferating cancer cells . The inhibition of NAMPT is shown to induce cell death and reduce osteoclastogenesis in MM [10,11].
In contrast, little is known about the function of lysosomal trafficking regulator (LYST) in human cancer. The expression of LYST is shown to affect lysosomal size, granule size, and autophagy in human cells . Mutation of LYST gene is associated with Chediak-Higashi syndrome (CHS), a rare autosomal recessive lysosomal disorder with hematological and immunological abnormalities . Besides CHS, mutation in LYST gene is one of the key factors that cause hemophagocytic lymphohistiocytosis, a deficiency in immune system function, and life-threatening disease characterized by uncontrolled T-cell and macrophage activation . In hemophagocytic lymphohistiocytosis, LYST plays an important role in controlling the terminal maturation of perforin-containing granules into secretory granules in cytotoxic T lymphocytes . The role of LYST gene in oncogenesis is still unclear, and dysregulation of LYST gene has never been described in MM, nor other cancers, before.
Our previous array-based comparative genomic hybridization findings revealed gains at chromosomal 7q22.3 and 1q42.3 regions in 92% and 47% of Malaysian MM patients (n = 63), respectively . More importantly, the NAMPT and LYST genes are located on 7q22.3 and 1q42.3, respectively. This led us to further study the functions of these genes in myeloma cell growth and survival by using small interfering RNA (siRNA) approach. Our findings provide a more profound understanding of the roles of NAMPT and LYST genes in the molecular pathogenesis of MM.
MATERIALS AND METHODS
The myeloma cell line RPMI 8226 was purchased from the American Type Culture Collection (ATCC, USA). Cells were cultured in RPMI-1640 medium (ATCC) supplemented with 10% of fetal bovine serum (Lonza, Switzerland). All cells were cultured in a humidified incubator at 37[degrees]C containing 5% C[O.sub.2]. The cells were passaged every 3-4 days.
Three unique siRNA duplexes for NAMPT (OriGene Cat. No.: SR306835, USA) and LYST (OriGene Cat. No.: SR300809, USA) were used to silence the respective gene in RPMI 8226 cells. The siRNAs were designated as NAMPT-a, NAMPT-b and NAMPT-c, and LYST-a, LYST-b and LYST-c. The siRNA sequences and their corresponding nucleotide binding sites are listed in Table 1. Approximately 200 nM of each siRNAs was used for transfection. Alternatively, pooled siRNAs were used (100 nM of each siRNA duplex). Pooled siRNAs were designated as NAMPT-abc and LYSTabc. Transfection of siRNAs into the RPMI 8226 myeloma cells was performed by Amaxa Nucleofection kit V (Lonza, Switzerland). Briefly, the cells were resuspended in 100 [micro]l of nucleofector V solution mixed with 100-300 nM of siRNAs or scrambled negative control siRNAs or 2 [micro]l of pmaxGFP at a density of 5.0 x [10.sup.6] cells/mL. The mixture was transferred to a cuvette and nucleofected using G-016 pulsing parameter with an Amaxa nucleofector apparatus (Lonza, Switzerland). Then, the cells were immediately transferred to pre-warmed culture medium in 12-well plates. Transfection efficiencies were determined by quantitative real time reverse transcriptase PCR (RT-qPCR) at 24 and 48 hours post-transfection. Each transfection was performed in two replicates and in two independent experiments.
Total RNA extraction and first strand cDNA synthesis
Total RNAs were isolated from the cells according to the manufacturer's protocol (Qiagen miRNeasy mini kit, Germany). On-column DNA digestion was performed with the RNase-free DNase set to eliminate DNA contamination during RNA purification (Qiagen DNase I, Germany). Five hundred nanograms of RNAs were reverse transcribed to cDNA in a final volume of 20 [micro]l reaction containing x1 reverse transcriptase buffer and enzyme mix (High capacity RNA-tocDNA kit, Applied Biosystems, USA). The reaction was incubated at 37[degrees]C for 1 hour and stopped at 95[degrees]C for 10 minutes in a thermal cycler.
Quantitative real-time PCR (qPCR)
A pre-designed TaqMan probe was used to quantitate the NAMPT (Life Technologies Cat. No.: Hsoo237i84, USA) and LYST (Life Technologies Cat. No.: Hsoo9i5897_mi, USA) gene expression. Each 20 [micro]l reaction was prepared in triplicate containing TaqMan Gene Expression Master Mix (Life Technologies, USA), a FAM dye-labeled TaqMan Gene Expression Assay (Life Technologies, USA), and 50 ng of cDNA. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as endogenous control to normalize sample input and minimize the variation between the treated and untreated samples (Life Technologies Cat. No.: Hs02758991_gi, USA). All qPCR reactions were run on an ABI 7500 Fast Real-time PCR System (Applied Biosystems, USA) in 96-well format, and the thermal cycling conditions were 95[degrees]C for 20 seconds followed by 40 cycles of 95[degrees]C for 3 seconds, and 60[degrees]C for 30 seconds. All samples were normalized to the endogenous control and fold changes were calculated through relative quantification ([2-.sup.[DELTA[DELTA]Ct]).
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazolium (MTT) assay for cell viability
The RPMI 8226 cells treated with siRNAs and scrambled negative control siRNAs were seeded onto 96-well plates at a density of 2.0 x [10.sup.4]/mL in triplicate (100 [micro]l/well). The cell proliferation was evaluated at 24, 48, and 72 hours post-transfection. Briefly, 10 [micro]l of MTT reagent (TREVIGEN, USA) at a concentration of 5 g/L was added to each well, and the cells were incubated for additional 4 hours at 37[degrees]C. Following incubation, 100 [micro]l of detergent reagent was added to each well, and the cells were incubated at 37[degrees]C for 2 hours. After the insoluble crystals were completely dissolved, the plate was read at absorbance of 570 nm using Odyssey' SA Imaging System (Li-Cor, Lincoln, USA).
Annexin-V staining for cell apoptosis detection
Annexin-V staining was performed using the Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (BioVision, USA). In this assay, Annexin V-FITC (1:100) and propidium iodide (PI, 0.5 [micro]g/mL) were used. Briefly, the cells treated with siRNAs and scrambled negative control siRNAs were collected by centrifugation. The cell pellet was washed with phosphate-buffered saline and resuspended in 500 [micro]l of binding buffer. Annexin V-FITC (1:100) and PI (0.5 [micro]g/mL) were added to the cell suspension and incubated for 10 minutes in the dark. Then, the cells were analyzed by FACSCalibur instrument (Becton Dickinson BD, USA). For each analysis, 10,000 events were recorded. Finally, the data generated were analyzed using the Cell Quest software (Becton Dickinson BD, USA).
Enzyme-linked immunosorbent assay (ELISA)
The cells transfected with siRNAs and scrambled negative control siRNAs were collected and lysed for 30 minutes on ice at 24 and 48 hours post-transfection. After centrifugation, supernatants were collected, and the total protein concentrations were measured by using the BCA assay kit (Thermo Scientific, USA). All the proteins were diluted to 500 pg/ml before applying the NAMPT Intracellular ELISA kit (BioVision, Switzerland). ELISA reactions were performed according to the manufacturer's instructions. Standard curve was generated using two-fold serial dilutions of the cells treated with control siRNA. All the samples and standards were loaded into the plate and incubated overnight at 4[degrees]C in duplicate. Following overnight incubation, the plate was washed and read at absorbance of 450 nm in an ELISA plate reader (TECAN Sunrise, Switzerland). The NAMPT protein concentrations were estimated from the standard curve equation.
Statistical analysis was performed using Student's f-test, and statistical significance was defined as p < 0.05. Data were expressed as mean [+ or -] standard deviation for two or three independent experiments.
Silencing of NAMPT and LYST with siRNA duplexes
In this study, pmaxGFP vectors were used to assess transfection success in RPMI 8226 myeloma cells. More than 80% of the cells expressed the green fluorescent signals at 24 hours post-transfection, indicating that the transfection was successfully procured (Figure 1A and B). The RT-qPCR results showed that the efficiency of NAMPT gene silencing was approximately 50% at 24 hours post-transfection when either NAMPT-a, NAMPT-b, or NAMPT-c siRNA was used (Figure 2A). The efficiency of gene knockdown decreased dramatically at 48 hours post-transfection for all three siRNA duplexes. When siRNA duplexes were pooled and NAMPT-abc was used for the transfection, the gene knockdown efficiency was increased by up to >70% at 24 hours post-transfection (20% higher compared to the single siRNAs). The stability of the gene knockdown effect was maintained at 48 hours post-transfection when the pooled siRNAs were used (Figure 2A).
In addition, the RT-qPCR results showed that the efficiency of LYST gene silencing was >70% at 24 hours post-transfection when either siRNA duplex (LYST-a, LYST-b, LYST-c, or LYST-abc) was used (Figure 2B). Given that siRNA pooling is known to significantly reduce off-target effects and increase target specificity (especially in the case of NAMPT gene knockdown), pooled siRNAs, NAMPT-abc and LYST-abc, were used for the rest of the functional analysis.
siRNA-mediated silencing of NAMPT and LYST inhibited proliferation of RPMI 8226 cells
A significant decrease in the cell growth was observed in NAMPT-abc- and LYST-abc-treated cells when compared to the cells transfected with scrambled negative control siRNAs (p < 0.05) (Figures 3A and B). These findings showed that the suppression of NAMPT or LYST gene led to the inhibition of cell proliferation in RPMI 8226 cells.
NAMPT and LYST induced apoptosis in RPMI 8226 cells
To investigate the biological impact of NAMPT or LYST inhibition on the apoptosis in myeloma cells, RPMI 8226 cells were transiently transfected with NAMPT-abc or LYST-abc siRNAs and the apoptotic cell death was measured using Annexin V-FITC/PI staining. The flow cytometry analysis showed that NAMPT-abc- and LYST-abc-treated cells significantly increased the numbers of early apoptotic cells compared to the cells treated with scrambled negative control, which was 26.9% versus 55.3% in NAMPT-abc-treated cells and 26.9% versus 41.5% in LYST-abc-treated cells (p < 0.05) (Figures 4A and B). This scenario indicated that silencing of NAMPT or LYST could induce apoptosis in RPMI 8226 myeloma cells.
Decreased protein expression level after the silencing of NAMPT gene
NAMPT protein expression levels in RPMI 8226 cells treated with siRNAs and scrambled negative control were estimated using ELISA assay. The OD readings indicated that the silencing of NAMPT gene using NAMPT-abc siRNAs resulted in a dramatic reduction of the NAMPT protein levels at 24, 48 and 72 hours post-transfection (p < 0.01) (Figure 5). Moreover, the ELISA assay showed that the protein expression levels were also reduced in NAMPT-b-treated cells, although the gene knockdown efficiencies for this siRNA were only about 50% at 24 and 48 hours post-transfection (Figure 2A and 5).
MM is a genomically complex heterogeneous disease composed of several molecular subtypes with varying clinicopathological features and disease outcomes . This disease remains incurable although advances in treatment have improved the overall survival rate of the patients. Drug resistance is the major problem in MM therapy, which highlights the importance of identifying new molecular targets for therapies, to combat this disease .
The [NAD.sup.+] is a pivotal signaling molecule, which is involved in maintaining the functions of a wide variety of [NAD.sup.+]-dependent enzymes in the cytoplasm and nucleus. NAMPT and nicotinamide mononucleotide adenylyltransferase (NMNAT) are two key enzymes included in the [NAD.sup.+] salvage pathway . NAMPT catalyses the conversion of NAM to NAM mononucleotide (NMN), which is then converted to [NAD.sup.+] by NMNAT . In humans, normal NAMPT expression is required during early embryo development, lymphocyte differentiation, muscle cell differentiation, maturation, and senescence [19-23]. In cancerous cells, more [NAD.sup.+] is needed to generate adenosine triphosphate, to supply energy for cell growth and survival . Therefore, NAMPT expression is expected to be higher in cancer patients. The elevation of NAD establishes conditions for transcription regulation via two highly [NAD.sup.+]-dependent enzymes: the protein deacetylase SIRT1 and poly-(ADP-ribose) polymerase (PARP1). Both SIRT1 and PARP1 play key roles in oncogenesis . It has been suggested that SIRT1 regulates gene transcription and chromatin structure through transcription factors, co-regulators, and histone modifications. Tumor protein p53, nuclear factor [kappa]B (NF[kappa]B), FOXO (Forkhead box O) proteins, estrogen receptor [alpha], liver X receptor, SRY-box 9 (SOX9), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1[alpha]), and p300 coactivator are all part of the critical downstream targets of SIRT1 [25-28]. Apart from that, PARP1 is involved in chromatin remodeling, transcription factor regulation, and DNA repair . Examples of transcription factors regulated by PARP1 include octamer transcription factor 1 (Oct-1), specificity protein 1 (SP1), peroxisome proliferator-activated receptor [gamma] (PPAR[gamma]), Smad3/Smad4, (sex determining region Y)-box 2 (SOX2), NF[kappa]B, and p300 . Some of these transcription factors, such as p53, NF[kappa]B, FOXO, and p300 are involved in the MM development and progression [6,31-33].
In this study, siRNAs were transiently transfected into RPMI 8226 myeloma cells through nucleofection method. Our results showed that the gene knockdown efficiency and stability of the gene silencing effects were increased when the pooled siRNA fragments were used. Thus, we showed that pooled siRNAs could improve gene knockdown efficiency and stability of the gene silencing effects, in addition to the ability to reduce off-target effects . Significant growth inhibition and apoptosis induction were detected in the siRNA-transfected cells demonstrating that NAMPT gene is a potential molecular target in myeloma therapy. More importantly, the reduction of NAMPT protein levels in NAMPT-b- and NAMPT-abc-treated cells suggests that the gene silencing had successfully suppressed the NAMPT translation in RPMI 8226 cells.
Recent studies have shown that the treatment of MM cell lines and xenograft models with FK866, a small molecule inhibitor, is able to inhibit NAMPT and induce MM cell death through autophagy mechanism. However, in these studies, the treatment of MM with FK866 did not induce cell death through apoptotic event [24,35]. The [NAD.sup.+] intracellular shortage, triggered by FK866 treatment, could cause autophagic cell death via two possible molecular mechanisms. First, autophagy is shown to be induced by inhibiting mammalian target of rapamycin signaling, a critical negative regulator of autophagy, along with a decrease in phosphoinositide 3-kinase and protein kinase B/AKT . Second, the autophagy mechanism is induced by transcriptional activation of several autophagy-related genes through the inhibition of mitogen-activated protein kinase signaling pathway and nuclear localization of transcription factor EB . Although these studies showed that MM cell death was induced by autophagy rather than apoptosis, it is possible that the pharmacological restriction of [NAD.sup.+] in MM cells triggers apoptotic signaling, which is then limited by concomitant onset of autophagy and the terminated apoptosis could then switch autophagy into MM cell death program. This explains why apoptosis cell death was not observed in the study of Cea et al. .
Unlike NAMPT, little is known about the function of LYST gene in human cancer. It has been shown that LYST gene is required for organizing endosomal resident proteins into late multivesicular endosomes by a mechanism that involves microtubules . Recent findings have shown that LYST plays an important role in the transportation of materials into lysosomes, a place where toxic substances and bacteria are broken down and digested. Furthermore, LYST helps in maintaining the lysosomal size and regulating its movement within cells . Our findings revealed that LYST gene was successfully knockdown by siRNAs in RPMI 8226 myeloma cells. For the first time, we showed that siRNA-mediated silencing of LYST inhibits proliferation and induces apoptosis in RPMI 8226 myeloma cells. The over-expression of LYST might contribute to the MM transformation and disease progression by activating cell proliferation and inhibiting apoptosis events.
Due to the budget constraint, the LYST protein expression level in the siRNA-transfected cells was not measured in the current study. Therefore, we are not certain whether LYST gene silencing has any impact on the protein translation. Since the ELISA kit for LYST protein detection is not commercially available, we aim to determine the effect of siRNA-mediated silencing of LYST on the protein expression by Western blot assay in our future research.
This study demonstrated that NAMPT and LYST genes play pivotal roles in the molecular pathogenesis of MM. This is the first report describing the possible functions of LYST in myelomagenesis and its potential role as a therapeutic target in MM.
This study was supported by research funding from the Ministry of Health, Malaysia (JPP-IMR: 12-035). The authors would like to thank the Director General of Health, Malaysia for his permission to publish the research findings and the Director of the Institute for Medical Research for her support in the publishing of this paper.
DECLARATION OF INTERESTS
The authors declare no conflict of interests.
 Eslick R, Talaulikar D. Multiple myeloma: From diagnosis to treatment. Aust Fam Physician. 2013;42(10):684-8.
 Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood. 2007409(8)5489-95. http://dx.doi.org/10.1182/blood-2006-08-040410.
 Omar ZA, Ibrahim Tamin NS. National cancer registry report: Malaysia cancer statistics-data and figure. Malaysia: National Cancer Registry; 2011. p. 85-7.
 Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM, et al DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):654-69. http://dx.doi.org/10.1002/wsbm.89.
 Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-72. http://dx.doi.org/10.1038/nature09837.
 Dimopoulos K, Gimsing P, GronbTh K. The role of epigenetics in the biology of multiple myeloma. Blood Cancer J. 2014;4:e207. http://dx.doi.org/10.1038/bcj.2014.29.
 Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004779(49)50754-63. http://dx.doi.org/10.1074/jbc.M408388200.
 Shackelford RE, Mayhall K, Maxwell NM, Kandil E, Coppola D. Nicotinamide phosphoribosyltransferase in malignancy: A review. Genes Cancer. 2013;4(11-12):447-56. http://dx.doi.org/10.1177/1947601913507576.
 Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome--A key determinant of cancer cell biology. Nat Rev Cancer. 2012;12(u):741-52. http://dx.doi.org/10.1038/nrc3340.
 de la Puente P, Muz B, Azab F, Luderer M, Azab AK. Molecularly targeted therapies in multiple myeloma. Leuk Res Treatment. 2014;2014:976567. DOI: 10.1155/2014/976567.
 Prideaux SM, Conway O'Brien E, Chevassut TJ. The RAG model: A new paradigm for genetic risk stratification in multiple myeloma. Bone Marrow Res. 2014;2014:526568. http://dx.doi.org/10.1155/2014/526568.
 Cullinane AR, Schaffer AA, Huizing M. The BEACH is hot: A LYST of emerging roles for BEACH-domain containing proteins in human disease. Traffic. 201344(7)749-66. http://dx.doi.org/10.1111/tra.12069.
 Al-Tamemi S, Al-Zadjali S, Al-Ghafri F, Dennison D. Chediak-Higashi syndrome: Novel mutation of the CHS1/LYST gene in 3 Omani patients. J Pediatr Hematol Oncol. 201456(4)7248-50. http://dx.doi.org/10.1097/MPH.0000000000000025.
 Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, Lehmberg K, et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood. 2011;118(17):4620-9. http://dx.doi.org/10.1182/blood-2011-05-356113.
 Sepulveda FE, Burgess A, Heiligenstein X, Goudin N, Menager MM, Romao M, et al. LYST controls the biogenesis of the endosomal compartment required for secretory lysosome function. Traffic. 2015;16(2):191-203. http://dx.doi.org/10.1111/tra.12244.
 Ivyna Bong PN, Ng CC, Lam KY, Megat Baharuddin PJ, Chang KM, Zakaria Z. Identification of novel pathogenic copy number aberrations in multiple myeloma: The Malaysian context. Mol Cytogenet. 2014;7(1):24. http://dx.doi.org/10.1186/1755-8166-7-24.
 Rongvaux A, Andris F, Van Gool F, Leo O. Reconstructing eukaryotic NAD metabolism. Bioessays. 2003;25(7):683-90. http://dx.doi.org/10.1002/bies.10297.
 Zhang T, Berrocal JG, Frizzell KM, Gamble MJ, DuMond ME, Krishnakumar R, et al. Enzymes in the NAD salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem. 2009;284(30):20408-17. http://dx.doi.org/10.1074/jbc.M109.016469.
 Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6(5):363-75. http://dx.doi.org/10.1016fj.cmet.2007.09.003.
 van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD--Dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005;97(1):25-34. http://dx.doi.org/10.1161/01.RES.0000173298.38808.27.
 van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, Cregan SP, et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem. 2007;282(15):10841-5. http://dx.doi.org/10.1074/jbc.C700018200.
 Fulco M, Cen Y Zhao P, Hoffman EP, McBurney MW Sauve AA, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell. 2008;14(5):661-73. http://dx.doi.org/10.1016/j.devcel.2008.02.004.
 Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol. 2008;181(7):4685-95. http://dx.doi.org/10.4049/jimmunol.181.7.4685.
 Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, et al. Targeting NAD salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012;120(17):3519-29. http://dx.doi.org/10.1182/blood-2012-03-416776.
 Kim MY, Woo EM, Chong YT, Homenko DR, Kraus WL. Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol. 200670(7)4479-93. http://dx.doi.org/10.1210/me.2005-0531.
 Michan S, Sinclair D. Sirtuins in mammals: Insights into their biological function. Biochem J. 2007;404(1):1-13. http://dx.doi.org/10.1042/BJ20070140.
 Dvir-Ginzberg M, Gagarina V, Lee EJ, Hall DJ. Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem. 2008;283(52):36300-10. http://dx.doi.org/10.1074/jbc.M803196200.
 Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, et al Specific SIRTi activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008;8(5)347-58. http://dx.doi.org/10.1016fj.cmet.2008.08.017.
 Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2(12):1134-49. http://dx.doi.org/10.1158/2159-8290.CD-12-0120.
 Ko HL, Ren EC. Functional aspects of PARP1 in DNA repair and transcription. Biomolecules. 2012;2(4):524-48. http://dx.doi.org/10.3390/biom2040524.
 Teoh PJ, Chng WJ. p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int. 2014;2014:717919. DOI: 10.1155/2014/717919.
 Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4(12):2186-207. http://dx.doi.org/10.18632/oncotarget.1497.
 Zhou Y, Uddin S, Zimmerman T, Kang JA, Ulaszek J, Wickrema A. Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma. 2008;49(10):1945-53. http://dx.doi.org/10.1080/10428190802304966.
 Hannus M, Beitzinger M, Engelmann JC, Weickert MT, Spang R, Hannus S, et al. siPools: Highly complex but accurately defined siRNA pools eliminate off-target effects. Nucleic Acids Res. 2014;42(12):8049-61. http://dx.doi.org/10.1093/nar/gku480.
 Cea M, Cagnetta A, Patrone F, Nencioni A, Gobbi M, Anderson KC. Intracellular [NAD.sup.+] depletion induces autophagic death in multiple myeloma cells. Autophagy. 2013;9(3):410-2. http://dx.doi.org/10.4161/auto.22866.
 Faigle W, Raposo G, Tenza D, Pinet V, Vogt AB, Kropshofer H, et al. Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: The Chediak-Higashi syndrome. J Cell Biol. 1998;141(5):1121-34. http://dx.doi.org/10.1083/jcb.141.5.1121.
Ivyna Pau Ni Bong (1,2), Ching Ching Ng (2) *, Shaik Kamal Fakiruddin (1), Moon Nian Lim (1), Zubaidah Zakaria (1)
(1) Haematology Unit, Cancer Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia, (2) Department of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
* Corresponding author: Ching Ching Ng, Department of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Wilayah Persekutuan Kuala Lumpur, 50603 Kuala Lumpur, Malaysia. Fax: +603-79675908, Tel: +603-79675872, E-mail: firstname.lastname@example.org
Submitted: 28 July 2016/Accepted: 20 August 2016
TABLE 1. siRNA sequences and their corresponding binding sites siRNA Sequences Nucleotide binding sites and referen sequence accession number NAMPT-a AGAAU CUUAAGUUGGCUAAAUU CAA 2938-2962 (NM_005746.2) NAMPT-b GACAUACCCUAUAGAAUUACUAACC 2354-2378 (NM_005746.2) NAMPT-c AACAUGUAGUGAGAACAAUAAGCAT 3604-3628 (NM_005746.2) LYST-a GGCACAGACGAUGUGAAUAUUCUCA 1681-1705 (NM_000081.3) LYST-b GCAUGAAACCUAAUAUGUAUAUGTT 13351-13375 (NM_000081.3) LYST-c ACUGUUCAGAAGUCACAAAGAGGAG 3182-3206 (NM_000081.3) siRNA: Small Interfering RNA, NAMPT: Nicotinamide phosphorlbosyltransferase, LYST: Lysosomal trafficking regulator FIGURE 2. Effects of transfection with small interfering RNA (siRNA) on nicotinamide phosphoribosyl transferase (NAMPT) and lysosomal trafficking regulator (LYST) mRNA levels in RPMI 8226 cells at 24 and 48 hours post-transfection, determined by quantitative real time reverse transcriptase PCR. (A) Cells were transfected with either NAMPT-a, NAMPT-b, NAMPT-c (200 nM) or pooled siRNAs NAMPT-abc (100 nM for each siRNA). (B) Cells were transfected with either LYST-a, LYST-b, LYST-c (200 nM) or pooled siRNAs LYST-abc (100 nM for each siRNA). * p < 0.05 compared with the control A NAMPT gene knockddown(%) 24h 48h NAMPT-a 41.8 23.7 NAMPT-b 56.2 49.3 NAMPT-c 43.7 35.8 NAMPT-abc 71.5 73.8 B LYST gene knockddown(%) 24h 48h LYST-a 83.5 76.9 LYST-b 68.7 64.3 LYST-c 77.9 57.3 LYST-abc 87.8 56.3 Note: Table made from bar graph. FIGURE 4. Apoptosis detection in RPMI 8226 cells with small interfering RNA (siRNA)-mediated silencing of nicotinamide phosphoribosyl transferase (NAMPT) or lysosomal trafficking regulator (LYST) gene at 48 hours post-transfection, analyzed by flow cytometry. (A) Scatter graphs show early and late apoptotic cells among RPMI 8226 cells treated with scrambled negative control, NAMPT-abc, and LYST-abc siRNAs. (B) Histograms show the numbers of early and late apoptotic cells among RPMI 8226 cells treated with NAMPT-abc and LYST-abc siRNAs compared to the cells treated with scrambled negative control. * p < 0.05 compared with the control. B Apoptotic cells (%) Control NAMPT-abc early apoptosis 26.9 55.3 late apoptosis 15.8 27.5 Apoptotic cells (%) Control LYST-abc early apoptosis 26.9 41.5 late apoptosis 15.8 18.0 Note: Table made from bar graph.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RESEARCH ARTICLE|
|Author:||Bong, Ivyna Pau Ni; Ng, Ching Ching; Fakiruddin, Shaik Kamal; Lim, Moon Nian; Zakaria, Zubaidah|
|Publication:||Bosnian Journal of Basic Medical Sciences|
|Date:||Nov 1, 2016|
|Previous Article:||Unknown primary adenocarcinomas: a single-center experience.|